1. Home
  2. ETV vs IOVA Comparison

ETV vs IOVA Comparison

Compare ETV & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

ETV

Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

HOLD

Current Price

$14.89

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$4.02

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETV
IOVA
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2005
2008

Fundamental Metrics

Financial Performance
Metric
ETV
IOVA
Price
$14.89
$4.02
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$9.00
AVG Volume (30 Days)
173.5K
13.8M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.84
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$47.74
Revenue Next Year
N/A
$40.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.13
$1.67
52 Week High
$14.83
$5.63

Technical Indicators

Market Signals
Indicator
ETV
IOVA
Relative Strength Index (RSI) 63.41 56.95
Support Level $14.05 $2.07
Resistance Level N/A $4.27
Average True Range (ATR) 0.18 0.28
MACD 0.02 0.07
Stochastic Oscillator 94.81 62.81

Price Performance

Historical Comparison
ETV
IOVA

About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest

Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: